|Articles|April 22, 2022
Nitrosamine Control: Understanding the New FDA and EMA Regulations
Author(s)SGS
This technical bulletin discusses major regulatory updates, introduced by the FDA and EMA, regarding nitrosamines and SGS proposed risk assessment method for compliance.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
3
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
4
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
5
